JP2009536834A - 癌の診断及び治療のための方法及び組成物 - Google Patents

癌の診断及び治療のための方法及び組成物 Download PDF

Info

Publication number
JP2009536834A
JP2009536834A JP2009511179A JP2009511179A JP2009536834A JP 2009536834 A JP2009536834 A JP 2009536834A JP 2009511179 A JP2009511179 A JP 2009511179A JP 2009511179 A JP2009511179 A JP 2009511179A JP 2009536834 A JP2009536834 A JP 2009536834A
Authority
JP
Japan
Prior art keywords
fgfr2
antibody
gene
colorectal cancer
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536834A5 (https=
Inventor
ジョン チャント，
アンソニー エス． ゲレロ，
ピーター ハヴァティ，
シンシア ホンチェル，
ケニス ユング，
トーマス ウー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2009536834A publication Critical patent/JP2009536834A/ja
Publication of JP2009536834A5 publication Critical patent/JP2009536834A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2009511179A 2006-05-12 2007-05-11 癌の診断及び治療のための方法及び組成物 Pending JP2009536834A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79977206P 2006-05-12 2006-05-12
PCT/US2007/068737 WO2007134210A2 (en) 2006-05-12 2007-05-11 Methods and compositions for the diagnosis and treatment of cancer

Publications (2)

Publication Number Publication Date
JP2009536834A true JP2009536834A (ja) 2009-10-22
JP2009536834A5 JP2009536834A5 (https=) 2010-07-01

Family

ID=38694721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511179A Pending JP2009536834A (ja) 2006-05-12 2007-05-11 癌の診断及び治療のための方法及び組成物

Country Status (5)

Country Link
US (2) US8945572B2 (https=)
EP (1) EP2018442A2 (https=)
JP (1) JP2009536834A (https=)
CA (1) CA2651755A1 (https=)
WO (1) WO2007134210A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529076A (ja) * 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
WO2014007369A1 (ja) * 2012-07-05 2014-01-09 独立行政法人国立がん研究センター Ｆｇｆｒ２融合遺伝子

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
CA2651755A1 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
PL2365828T3 (pl) 2008-11-07 2015-04-30 Galaxy Biotech Llc Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
US20100136560A1 (en) * 2008-12-02 2010-06-03 The Johns Hopkins University Integrated Analyses of Breast and Colorectal Cancers
US20120301482A1 (en) * 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
AU2010319327B2 (en) 2009-11-13 2015-08-13 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
US20140141996A1 (en) * 2011-06-22 2014-05-22 Oncocyte Corporation Methods and Compositions for the Treatment and Diagnosis of Cancer
JP2015505818A (ja) 2011-11-14 2015-02-26 ファイブ プライム セラピューティックス インコーポレイテッド 癌を治療する方法
AU2012351685A1 (en) * 2011-12-14 2014-07-03 Seattle Genetics, Inc. FGFR antibody drug conjugates (ADCs) and the use thereof
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
PH12021552742A1 (en) 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
US20170145103A1 (en) * 2015-11-23 2017-05-25 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863888A (en) * 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
US6900053B2 (en) 2001-09-14 2005-05-31 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 2 expression
JP2002505431A (ja) * 1998-02-25 2002-02-19 アメリカ合衆国 迅速な分子プロファイリングのための細胞アッセイ法
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
WO2000024940A1 (en) * 1998-10-28 2000-05-04 Vysis, Inc. Cellular arrays and methods of detecting and using genetic disorder markers
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
IL128380A0 (en) * 1999-02-04 2000-01-31 Yeda Res & Dev A method of screening for agonists and antagonists of FGFR
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU2001275337A1 (en) * 2000-06-07 2001-12-17 Lexicon Genetics Incorporated Novel human transporter proteins and polynucleotides encoding the same
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7537905B2 (en) * 2003-01-15 2009-05-26 The Regents Of The University Of California Amplified and overexpressed gene in colorectal cancers
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
CA2550245A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US7872016B2 (en) 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
EP1871911A2 (en) * 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
CA2651755A1 (en) 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6012029531; Ｎａｔｕｒｅ，　１９９９，　４０２，　ｐｐ．７１５-７２０ *
JPN6012036803; Ｐａｔｈｏｌ．　Ｉｎｔ．，　２０００，　５０（５），　ｐｐ．３６３-３７２ *
JPN6012036805; Ｃｌｉｎ．　Ｃａｎｃｅｒ　Ｒｅｓ．，　１９９６，　２（８），　ｐｐ．１３７３-１３８１ *
JPN6012036808; Ｂｒｅａｓｔ　Ｃａｎｃｅｒ　Ｒｅｓ．，　２０００，　２（４），　ｐｐ．３１１-３２０ *
JPN6012036810; Ｃｌｉｎ．　Ｃａｎｃｅｒ　Ｒｅｓ．，　２００３，　９（１４），　ｐｐ．５２７１-５２８１ *
JPN6012036812; Ｊ．　Ｎｉｈｏｎ　Ｍｅｄ．　Ｓｃｈ．，　２００１，　６８（５），　ｐｐ．３９７-４０４ *
JPN6012036814; Ｏｎｃｏｇｅｎｅ，　２００４，　２３（５７），　ｐｐ．９２０１-９２１１ *
JPN6012036815; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ．，　１９９３，　２６８（１３），　ｐｐ．９１８０-９１８３ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529076A (ja) * 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
WO2014007369A1 (ja) * 2012-07-05 2014-01-09 独立行政法人国立がん研究センター Ｆｇｆｒ２融合遺伝子

Also Published As

Publication number Publication date
WO2007134210A8 (en) 2009-07-30
US20150167101A1 (en) 2015-06-18
EP2018442A2 (en) 2009-01-28
CA2651755A1 (en) 2007-11-22
WO2007134210A2 (en) 2007-11-22
US20090311250A1 (en) 2009-12-17
US8945572B2 (en) 2015-02-03
WO2007134210A3 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
US8945572B2 (en) Methods and compositions for the diagnosis and treatment of cancer
JP2010509922A (ja) 腫瘍と関連している遺伝的変異
NZ563370A (en) Compositions and methods for the diagnosis and treatment of tumor
KR101881168B1 (ko) 약물 저항성과 관련된 유전적 변이
JP2012177698A (ja) 癌の予後予測方法、診断方法及び治療方法
JP5596975B2 (ja) 腫瘍と関連している遺伝的変異
US20090098115A1 (en) Cell lines and animal models of HER2 expressing tumors
US20150376289A1 (en) Methods and compositions for the diagnosis and treatment of cancer
JP5297375B2 (ja) 癌の診断及び治療のための方法及び組成物
HK1108924B (en) Cancer prognostic methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130514